Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$11.00 USD
+0.04 (0.36%)
Updated May 24, 2024 03:59 PM ET
After-Market: $10.99 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Inovio Pharmaceuticals, Inc. [INO]
Reports for Purchase
Showing records 201 - 220 ( 363 total )
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MERS Vaccine Delivers Positive Phase 1 Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1/2 Trial in Brain Cancer Starts Patient Treatment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Durable Immune Responses in Relapsed Prostate Cancer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HIV Vaccine Delivers Robust and Durable Immune Responses; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2018 1Q Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Potential $56M in Non-Dilutive Funding for Lassa Fever and MERS Vaccines; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ApolloBio License and Collaboration Agreement Closed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2017 Financial Results Reported; Positive Phase 1 HBV Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Tuberculosis and Malaria Vaccine Development Funding Received; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Preclinical Results for a Broadly Protective Flu Vaccine; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Parker Institute Collaboration; Milestone Payment from MedImmune; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ApolloBio Agreement Amended With $23M Upfront Payment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Evidence of Synergy Between TERT and Checkpoint Inhibitors Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R